Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

17.77 -0.01 (-0.06%)
Streaming Delayed Price Updated: 11:14 AM EDT, Aug 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 147,142
Open 17.78
Bid (Size) 17.76 (600)
Ask (Size) 17.78 (300)
Prev. Close 17.78
Today's Range 17.72 - 17.93
52wk Range 9.200 - 19.26
Shares Outstanding 1,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
STOCK ALERT: Kaskela Law Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages Current AMRX Stockholders to Contact the Firm
From Kaskela Law
Via Business Wire
News headline image
1 Russell 2000 Stock with Exciting Potential and 2 We Ignore
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,... 
Via StockStory

Performance

YTD
+40.4%
+40.4%
1 Month
-1.8%
-1.8%
3 Month
+38.9%
+38.9%
6 Month
+23.2%
+23.2%
1 Year
+91.5%
+91.5%

More News

Read More
News headline image
Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
1 Healthcare Stock Worth Your Attention and 2 We Ignore
Via StockStory
Amneal Pharmaceuticals (NASDAQ:AMRX) Soars on Q2 Earnings Beat and Raised Guidance ↗
Via Chartmill
Topics Earnings
News headline image
5 Insightful Analyst Questions From Amneal’s Q2 Earnings Call
Via StockStory
Topics Earnings World Trade
News headline image
AMRX Q2 Deep Dive: Diversified Product Mix and Biosimilars Strategy Shape Guidance
Via StockStory
News headline image
Amneal (AMRX) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Amneal Pharmaceuticals Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Amneal (NASDAQ:AMRX) Beats Expectations in Strong Q2 CY2026, Stock Jumps 15.9%
Via StockStory
News headline image
Amneal Reports Second Quarter 2026 Financial Results
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal (AMRX) Reports Q2: Everything You Need To Know Ahead Of Earnings
Via StockStory
News headline image
Spotting Winners: Amneal (NASDAQ:AMRX) And Generic Pharmaceuticals Stocks In Q1
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Kaskela Law LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages AMRX Shareholders to Contact the Firm
From Kaskela Law LLC
Via Business Wire
News headline image
Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
3 Reasons AMRX is Risky and 1 Stock to Buy Instead
Via StockStory
Topics Stocks
News headline image
Amneal to Report Second Quarter 2026 Results on July 30, 2026
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
1 Mooning Stock Worth Your Attention and 2 We Question
Via StockStory
News headline image
1 Small-Cap Stock for Long-Term Investors and 2 We Find Risky
Via StockStory
News headline image
3 Russell 2000 Stocks with Open Questions
Via StockStory
News headline image
Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase ↗
Via MarketBeat
News headline image
Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Why Amneal (AMRX) Stock Is Trading Up Today
Via StockStory
News headline image
Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution
From Amneal Pharmaceuticals LLC
Via GlobeNewswire

Frequently Asked Questions

Is Amneal Pharmaceuticals, Inc. - Class A Common Stock publicly traded?
Yes, Amneal Pharmaceuticals, Inc. - Class A Common Stock is publicly traded.
What exchange does Amneal Pharmaceuticals, Inc. - Class A Common Stock trade on?
Amneal Pharmaceuticals, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Amneal Pharmaceuticals, Inc. - Class A Common Stock?
The ticker symbol for Amneal Pharmaceuticals, Inc. - Class A Common Stock is AMRX on the Nasdaq Stock Market
What is the current price of Amneal Pharmaceuticals, Inc. - Class A Common Stock?
The current price of Amneal Pharmaceuticals, Inc. - Class A Common Stock is 17.77
When was Amneal Pharmaceuticals, Inc. - Class A Common Stock last traded?
The last trade of Amneal Pharmaceuticals, Inc. - Class A Common Stock was at 08/25/26 11:14 AM ET
What is the market capitalization of Amneal Pharmaceuticals, Inc. - Class A Common Stock?
The market capitalization of Amneal Pharmaceuticals, Inc. - Class A Common Stock is 17.77K
How many shares of Amneal Pharmaceuticals, Inc. - Class A Common Stock are outstanding?
Amneal Pharmaceuticals, Inc. - Class A Common Stock has 18K shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.